[
  {
    "objectID": "Gastric_Cancer.html",
    "href": "Gastric_Cancer.html",
    "title": "2  Gastric Cancer",
    "section": "",
    "text": "&lt;!DOCTYPE html PUBLIC “-//W3C//DTD HTML 4.01 Transitional//EN”&gt;\n\n\n\n\nGASTRIC CANCER\n\n\n\n\n\n\nGastric Cancer\n\n\n\n\nDEFINITION Primary malignancy of the stomach, often a highly invasive disease associated with high mortality. \n\ntop D I A B M I M home\n\n&lt;p&gt; &lt;/p&gt;\n&lt;hr&gt; &lt;b&gt;&lt;a name=\"incidence\"&gt;INCIDENCE&lt;br&gt;\n    &lt;br&gt;\n  &lt;/a&gt;&lt;/b&gt; Common worldwide (4th biggest cancer, 2nd biggest killer)&lt;br&gt;\nReducing in West; used to be highest killer; now 1/3 what it was 35\nyrs ago (poss. related to H. Pylori).&lt;br&gt;\n(Trend is decreasing distal, increasing cardia/GOJ, increase in\ndiffuse type, represents 30% of neoplasms.&lt;br&gt;\n&lt;u&gt;&lt;br&gt;\n  Geography&lt;/u&gt;&lt;br&gt;\nRelatively low in West, high in SE Asia, Japan (decreasing with\nWesternization), Russia, S America.&lt;br&gt;\n2-4x in Polynesians.&lt;br&gt;\n&lt;u&gt;&lt;br&gt;\n  Sex&lt;/u&gt;&lt;br&gt;\nM2:F1.&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"text-decoration: underline;\"&gt;Age&lt;/span&gt;&lt;br\n  style=\"text-decoration: underline;\"&gt;\nMean 60s at discovery&lt;br&gt;\nRare under 40 except in familial forms.&lt;br&gt;\n&lt;br&gt;\n&lt;center&gt;&lt;a href=\"#top\"&gt;top&lt;/a&gt; &lt;a href=\"#definition\"&gt;D&lt;/a&gt; &lt;a\n    href=\"#incidence\"&gt;I&lt;/a&gt; &lt;a href=\"#aetiology\"&gt;A&lt;/a&gt; &lt;a\n    href=\"#biologicalbehaviour\"&gt;B&lt;/a&gt; &lt;a href=\"#manifestations\"&gt;M&lt;/a&gt;\n  &lt;a href=\"#investigations\"&gt;I&lt;/a&gt; &lt;a href=\"#management\"&gt;M&lt;/a&gt; &lt;a\n    href=\"home.html\"&gt;home&lt;/a&gt;&lt;/center&gt;\n&lt;p&gt; &lt;/p&gt;\n&lt;hr&gt; &lt;b&gt;&lt;a name=\"aetiology\"&gt;AETIOLOGY&lt;/a&gt;&lt;/b&gt;&lt;br&gt;\n&lt;br&gt;\nGastric CA = 90% adenocarcinomas.&lt;br&gt;\n10% others (mainly lymphoma, GIST).&lt;br&gt;\nOccasional others: SCC, oat cell carcinoma, carcinoid, mesodermal\ntumours etc.&lt;br&gt;\n&lt;br&gt;\n&lt;u&gt;AdenoCa Predisposing factors&lt;/u&gt;&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;Genetic&lt;/span&gt;&lt;br&gt;\n&lt;span style=\"font-weight: bold;\"&gt;Familial Gastric cancer&lt;/span&gt;&lt;br&gt;\n1. Hereditary diffuse gastric cancer&lt;br&gt;\n- 2 or more cases in first/second degree relatives; one diagnosed\nbefore 50&lt;br&gt;\n- 3 or more independent of age&lt;br&gt;\n- E-cadherin gene inactivating mutation&lt;br&gt;\n- esp common in Maori.&lt;br&gt;\n2. Familial diffuse gastric cancer&lt;br&gt;\n3. Familial intestinal gastric cancer&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;Inflammatory&lt;/span&gt;&lt;br&gt;\nChronic gastritis usual background.&lt;br&gt;\n&lt;i style=\"font-weight: bold;\"&gt;H. pylori&lt;/i&gt;&lt;span style=\"font-weight:\n  bold;\"&gt; main cause of this (3-4x risk if infected).&lt;/span&gt;&lt;br&gt;\n- risk proportionate to H pylori serum levels.&lt;br&gt;\nAtrophy of gastric mucosa (decreased acidity, more bacteria, produce\ntoxins), assoc. with pernicious anaemia.&lt;br&gt;\nAlso chronic peptic ulcers.&lt;br&gt;\n- not significantly (h. pylori is), but 1% associated by virtue of\nchronic inflammatory change.&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;Nutritional&lt;/span&gt;&lt;br&gt;\nVitamin C deficiency.&lt;br&gt;\nLow fruit and veg, high starch.&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;Toxins&lt;/span&gt;&lt;br&gt;\nSmoking.&lt;br&gt;\nDietary toxins (nitrosamines, ?polycyclic hydrocarbons, dried,\nsmoked and salted food).&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;Iatrogenic&lt;/span&gt;&lt;br&gt;\nPrevious gastric surgery.&lt;br&gt;\n- 2% risk of cancer at a gastroduodenal anastomosis&lt;br&gt;\n- typically 15-20y after surgery; young surgical at risk.&lt;br&gt;\n- chronic gastritis and atrophy, fundic gland polyps, hyperplastic\npolyps also more common in the remnant.&lt;br&gt;\n- both intestinal and diffuse types, 40% early, &lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;Other&lt;/span&gt;&lt;br&gt;\nAlso in blood group A people; ?why.&lt;br&gt;\nMenetrier's Disease&lt;br&gt;\n- rare; rugal hypertrophy and hyperplasia, hypochlorhydria and\nprotein-losing enteropathy.&lt;br&gt;\n- cancer in 10%, often diagnosed within 12mo of each other.&lt;br&gt;\n&lt;br&gt;\n&lt;center&gt;&lt;a href=\"#top\"&gt;top&lt;/a&gt; &lt;a href=\"#definition\"&gt;D&lt;/a&gt; &lt;a\n    href=\"#incidence\"&gt;I&lt;/a&gt; &lt;a href=\"#aetiology\"&gt;A&lt;/a&gt; &lt;a\n    href=\"#biologicalbehaviour\"&gt;B&lt;/a&gt; &lt;a href=\"#manifestations\"&gt;M&lt;/a&gt;\n  &lt;a href=\"#investigations\"&gt;I&lt;/a&gt; &lt;a href=\"#management\"&gt;M&lt;/a&gt; &lt;a\n    href=\"home.html\"&gt;home&lt;/a&gt;&lt;/center&gt;\n&lt;p&gt; &lt;/p&gt;\n&lt;hr&gt; &lt;b&gt;&lt;a name=\"biologicalbehaviour\"&gt;BIOLOGICAL BEHAVIOUR&lt;/a&gt;&lt;/b&gt;&lt;br&gt;\n&lt;u&gt;&lt;br&gt;\n  Pathology&lt;/u&gt;&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;AdenoCa&lt;/span&gt;&lt;br&gt;\n&lt;span style=\"font-weight: bold;\"&gt;&lt;br&gt;\n  Lauren Classification&lt;/span&gt;:&lt;br&gt;\n- &lt;span style=\"text-decoration: underline;\"&gt;Intestinal&lt;/span&gt; (well\ndifferentiated; mucosal origin) &lt;br&gt;\n- or &lt;span style=\"text-decoration: underline;\"&gt;diffuse&lt;/span&gt;\n(poorly differentiated; lamina propria origin)&lt;br&gt;\n&lt;span style=\"font-weight: bold;\"&gt;&lt;br&gt;\n  1. &lt;/span&gt;&lt;span style=\"font-style: italic; font-weight: bold;\"&gt;Intestinal&lt;/span&gt;&lt;span\n  style=\"font-weight: bold;\"&gt; &lt;/span&gt;(20% 5-yr survival)&lt;br&gt;\n&lt;span style=\"font-weight: bold;\"&gt;-&lt;/span&gt; associated with chronic\ngastritis and intestinal metaplasia, H. pylori.&lt;br&gt;\n- tend to be well differentiated and expansile&lt;br&gt;\n- high risk populations, M&gt;F 2:1; older pts; declining&lt;br&gt;\n- tends to form glands and met via blood.&lt;br&gt;\n&lt;span style=\"font-weight: bold;\"&gt;&lt;br&gt;\n  2.&lt;/span&gt;&lt;span style=\"font-style: italic; font-weight: bold;\"&gt;\n  Diffuse&lt;/span&gt; are ominous (10% 5-yr survival)&lt;br&gt;\n- no elements secrete mucous; unclear cause; ?genetic, ?h. pylori&lt;br&gt;\n- tend to be poorly differentiated and infiltrative&lt;br&gt;\n- tend to affect F&gt;M, younger pts and may be more genetically\ndetermined.&lt;br&gt;\n- spreads via submucosal infiltration&lt;br&gt;\n&lt;br&gt;\n&lt;u&gt;Pathogenesis&lt;/u&gt;&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt; Classical development theorized\n  as: &lt;/span&gt;&lt;br&gt;\n-&gt; H pylori infection&lt;br&gt;\n-&gt; Acute gastritis&lt;br&gt;\n-&gt; chronic active gastritis&lt;br&gt;\n-&gt; atrophic gastritis&lt;br&gt;\n-&gt; intestinal metaplasia&lt;br&gt;\n-&gt; dysplasia&lt;br&gt;\n-&gt; gastric cancer&lt;br&gt;\nThis is not fixed; 60-70% of mild-mod dysplasia may revert to\nnormal; severe = much more likely to progress.&lt;br&gt;\nThis only applies to intestinal type; diffuse tend not to have\nassociation with chronic gastritis / atrophy.&lt;br&gt;\n&lt;br&gt;\n&lt;u&gt; Natural History&lt;/u&gt;&lt;br&gt;\nArises in the mucosa.&lt;span style=\"font-style: italic;\"&gt;&lt;br&gt;\n  &lt;br&gt;\n  &lt;span style=\"font-weight: bold;\"&gt;Early Gastric Ca&lt;/span&gt;&lt;br&gt;\n&lt;/span&gt;When confined to the mucosa or submucosa, regardless of lymph\ninvolvement.&lt;br&gt;\n5 yr survival of such cancer good (90%), diagnosis in West very poor\n(10% early)&lt;br&gt;\n- in Japan, screening with double contrast barium meal and endoscopy\nmeans more (e.g. 30%) detected early.&lt;br&gt;\n- better when confined to submucosa (90%) vs submucosa (75%) - 15 yr\nsurvivals.&lt;br&gt;\nPredominantly distal stomach, most 2-5cm; if &lt;5mm then 'minute'.&lt;span\n  style=\"font-weight: bold;\"&gt;&lt;br&gt;\n&lt;/span&gt;LN risk &lt;5% with mucosal disease; 20% with submucosal\ninvasion.&lt;br&gt;\n- higher risk with ulceration, larger tumours&lt;br&gt;\n&lt;span style=\"font-weight: bold;\"&gt;&lt;br&gt;\n  Early Gastric Ca Macroscopic Classification:&lt;/span&gt;&lt;br&gt;\n&lt;span style=\"text-decoration: underline;\"&gt;Type I:&lt;/span&gt; protuberant&lt;br&gt;\n- sessile, smooth nodules with a broad stalk, often pale&lt;br&gt;\n&lt;span style=\"text-decoration: underline;\"&gt;Type II&lt;/span&gt;:\nsuperficial (a=elevated; b=flat; c=depressed)&lt;br&gt;\n- slightly &lt;br&gt;\n&lt;span style=\"text-decoration: underline;\"&gt;Type III&lt;/span&gt;:\nulcerating&lt;br&gt;\nExophytic tumours = better prognosis (more intestinal type);\nUlcerating = diffuse.&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-style: italic; font-weight: bold;\"&gt;Location&lt;/span&gt;&lt;br&gt;\nCommonest in the antrum (40%), but diffuse cancers of prox stomach\n(30%) becoming more common in West, unclear why.&lt;br&gt;\nSpread into the duodenum is a poor prognostic sign (5-yr survival\napproaching 5%).&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-style: italic; font-weight: bold;\"&gt;Spread&lt;/span&gt;&lt;br&gt;\nIntramural, direct extraluminal growth, lymph, and mets.&lt;br&gt;\n- involves regional nodes at least in 3/4 at presentation.&lt;br&gt;\nIntragastric spread often proximal &gt; distal&lt;br&gt;\n- pylorus is a partial barrier; tumor in 25% past bulb still.&lt;br&gt;\nLater liver, bone, brain, lung.&lt;br&gt;\n5 yr survival rate for advanced Ca is below 15%.&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"text-decoration: underline;\"&gt;&lt;span style=\"font-weight:\n    bold;\"&gt;Subtypes : Borrman Classification&lt;/span&gt;&lt;br&gt;\n&lt;/span&gt;Four subdivisions correlate loosely with natural history and\noutcome&lt;br&gt;\nIn order of nastiness:&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;I. Polypoid carcinomas&lt;/span&gt;&lt;br\n  style=\"font-style: italic;\"&gt;\n- large, bulky intraluminal growths that tend to metastasize late.&lt;br&gt;\n- often soft and red in colour with a broad base&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;II. Ulcerating / excavated\n  carcinoma&lt;/span&gt;&lt;br style=\"font-style: italic;\"&gt;\n- deep penetrating ulcer-tumor; all layers deep&lt;br&gt;\n- flat edges instead of rolled edges&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;III. Ulcerative with elevated\n  margins, infiltrated&lt;/span&gt;&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;IV. Linitis plastica&lt;/span&gt; type&lt;br&gt;\n- all layers thick, spreads with a marked desmoplastic reaction.&lt;br&gt;\n- cure is rare, spread advanced&lt;span style=\"font-style: italic;\"&gt;&lt;/span&gt;&lt;br&gt;\n&lt;u&gt;&lt;br&gt;\n&lt;/u&gt;*There is also a lymphoepithelioma-like carcinoma, often\nassociated with EBV, with a relatively good prognosis.&lt;u&gt;&lt;br&gt;\n  &lt;br&gt;\n  &lt;span style=\"font-weight: bold;\"&gt;Genetics&lt;/span&gt;&lt;/u&gt;&lt;br&gt;\nDisruption of the genome, participation of oncogenes, mutation of\ntumor-suppressor genes.&lt;u&gt;&lt;span style=\"font-weight: bold;\"&gt;&lt;/span&gt;&lt;br&gt;\n&lt;/u&gt;p53 is most common abnormality; tumour suppressor gene involved\nin preserving stability during DNA turnover&lt;u&gt;&lt;br&gt;\n&lt;/u&gt;- if not, then usually microsatellite instability; different\npathway for collecting genetic abnormalities.&lt;br&gt;\nAPC and DCC genes also commonly affected.&lt;br&gt;\nE-cadherin (cellular adhesion molecules) reduced expression in 90%,\nesp diffuse types.&lt;br&gt;\nFamilial clustering in HNPCC and familial gastric cancer.&lt;br&gt;\n&lt;u&gt;&lt;br&gt;\n  &lt;span style=\"font-weight: bold;\"&gt;Complications&lt;/span&gt;&lt;/u&gt;&lt;br&gt;\nLate cancers risk perforation.&lt;br&gt;\nLocal perf with abscess, internal or external fistula possible,\nespecially in the ulcerating form.&lt;br&gt;\n&lt;br&gt;\n&lt;center&gt;&lt;a href=\"#top\"&gt;top&lt;/a&gt; &lt;a href=\"#definition\"&gt;D&lt;/a&gt; &lt;a\n    href=\"#incidence\"&gt;I&lt;/a&gt; &lt;a href=\"#aetiology\"&gt;A&lt;/a&gt; &lt;a\n    href=\"#biologicalbehaviour\"&gt;B&lt;/a&gt; &lt;a href=\"#manifestations\"&gt;M&lt;/a&gt;\n  &lt;a href=\"#investigations\"&gt;I&lt;/a&gt; &lt;a href=\"#management\"&gt;M&lt;/a&gt; &lt;a\n    href=\"home.html\"&gt;home&lt;/a&gt;&lt;/center&gt;\n&lt;br&gt;\n&lt;p&gt; &lt;/p&gt;\n&lt;hr&gt; &lt;b&gt;&lt;a name=\"manifestations\"&gt;MANIFESTATIONS&lt;/a&gt;&lt;/b&gt;&lt;br&gt;\n&lt;br&gt;\n&lt;b&gt;SYMPTOMS&lt;/b&gt;&lt;br&gt;\n&lt;br&gt;\n&lt;u&gt;Local&lt;/u&gt;&lt;br&gt;\nNo symptoms when superficial and curable.&lt;br&gt;\nLater varies from:&lt;br&gt;\n- vague non-specific symptoms e.g. early satiety, heaviness, not\nidentified as pain.&lt;br&gt;\n- to severe steady abdo pain (though this often slight and can be\nrelieved by food).&lt;br&gt;\nMay have had dyspepsia for years, but persistence is new.&lt;br&gt;\n&lt;br&gt;\nAnorexia (often w meat), dyspepsia, &lt;br&gt;\nNausea, vomiting (severe if near pylorus), and altered bowel habit\npossible.&lt;br&gt;\n&lt;br&gt;\nLess frequently dysphagia (if involves cardia)&lt;br&gt;\nHaemorrhage (haematemesis / malaena), perforation&lt;br&gt;\n&lt;br&gt;\n&lt;u&gt;General&lt;/u&gt;&lt;br&gt;\nLoss of weight and strength, malaise.&lt;br&gt;\nFrequently anaemic symptoms.&lt;br&gt;\n&lt;br&gt;\n&lt;u&gt;Metastatic&lt;/u&gt;&lt;br&gt;\nLocal spread.&lt;br&gt;\nSymptoms from lymph, liver, bones, brain, lung.&lt;br&gt;\n&lt;br&gt;\n&lt;b&gt;SIGNS&lt;/b&gt;&lt;br&gt;\n&lt;br&gt;\n&lt;u&gt;Observe&lt;/u&gt;&lt;br&gt;\nMay be jaundice, cachexia, anaemia.&lt;br&gt;\nIf metastatis - appropriate signs to liver, bone, brain, lung.&lt;br&gt;\nAssociated with dermatomyositis (non-suppurative inflammation of\nskin) and acanthosis nigricans (thickened, hyperpigmented skin at\nflexures).&lt;br&gt;\n&lt;br&gt;\n&lt;u&gt;Palpate&lt;/u&gt;&lt;span style=\"font-style: italic;\"&gt;; Advanced Disease&lt;/span&gt;&lt;br&gt;\nPalpable tumour usually means diagnosis too late.&lt;br&gt;\nVirchow's Node (left supraclavicular fossa); Sister Mary Joseph\nNodule &lt;br&gt;\n?Large liver &lt;br&gt;\n?Malignant ascites.&lt;br&gt;\nRectal or PV may show Blumer's shelf (pre-rectal mets) in advanced\ndisease.&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"text-decoration: underline;\"&gt;Metastatic&lt;/span&gt;&lt;br&gt;\nConsider also lungs, bone, brain.&lt;br&gt;\n&lt;center&gt;&lt;a href=\"#top\"&gt;top&lt;/a&gt; &lt;a href=\"#definition\"&gt;D&lt;/a&gt; &lt;a\n    href=\"#incidence\"&gt;I&lt;/a&gt; &lt;a href=\"#aetiology\"&gt;A&lt;/a&gt; &lt;a\n    href=\"#biologicalbehaviour\"&gt;B&lt;/a&gt; &lt;a href=\"#manifestations\"&gt;M&lt;/a&gt;\n  &lt;a href=\"#investigations\"&gt;I&lt;/a&gt; &lt;a href=\"#management\"&gt;M&lt;/a&gt; &lt;a\n    href=\"home.html\"&gt;home&lt;/a&gt;&lt;/center&gt;\n&lt;br&gt;\n&lt;p&gt; &lt;/p&gt;\n&lt;hr&gt; &lt;b&gt;&lt;a name=\"investigations\"&gt;INVESTIGATIONS&lt;/a&gt;&lt;/b&gt;&lt;br&gt;\n&lt;u&gt;&lt;br&gt;\n  Endoscopy&lt;/u&gt;&lt;br&gt;\nGastroscopic biopsy is standard, with biopsy for all pts with ulcer\n(6+ bxs)&lt;br&gt;\n- GC ulcers are suspect.&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;&lt;br&gt;\n  Role of EUS&lt;/span&gt;&lt;br&gt;\nCan show depth of tumor (80% accuracy), and lymph nodes (only 50%\naccuracy!)&lt;br&gt;\nBut specifically useful for the showing depth of invasion&lt;br&gt;\n- differentiating T2 tumours, which need neoadjuvant chemo and may\nbe amenable to EMR in specialist centres.&lt;br&gt;\n&lt;br&gt;\n&lt;u&gt;Imaging&lt;/u&gt;&lt;br&gt;\nStaging depends on CT, EUS and laparoscopy&lt;br&gt;\n- CT shows metastatic disease&lt;br&gt;\nAXR - stomach rigid if 'leather bottle'.&lt;br&gt;\nBa meal study (double contrast)&lt;br&gt;\n&lt;u&gt;&lt;br&gt;\n&lt;/u&gt;&lt;u&gt;Staging Laparoscopy&lt;/u&gt;&lt;br&gt;\nHighly advisable; done as a day stay procedure.&lt;br&gt;\nShows peritoneal metastatic disease in 30% of pts with normal\ncross-sectional imaging.&lt;br&gt;\nCollect peritoneal washings&lt;br&gt;\n- if +ve, predicts early peritoneal recurrence.&lt;br&gt;\n- in absence of visible mets, decreases survival from 98.5 months to\n14.8 months,&lt;br&gt;\n&lt;u&gt;&lt;br&gt;\n&lt;/u&gt;&lt;u&gt;&lt;i&gt;Role of PET&lt;/i&gt;&lt;u&gt;&lt;br&gt;\n  &lt;/u&gt;&lt;/u&gt;Less utility in gastric cancer as many are not FDG avid.&lt;br&gt;\n- only 60%; vs ~90% of esophageal cancers.&lt;br&gt;\nMore likely in intestinal-type tumours vs diffuse signet-ring type\ncancers.&lt;u&gt;&lt;br&gt;\n  &lt;br&gt;\n  Haematology&lt;/u&gt;&lt;br&gt;\nLeucocytosis possible.&lt;br&gt;\nMay be picked up on FOB (50% +ve)&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"text-decoration: underline;\"&gt;Markers&lt;/span&gt;&lt;br\n  style=\"text-decoration: underline;\"&gt;\nCEA +ve in 65%, usually with extensive disease&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"text-decoration: underline;\"&gt;Histology&lt;/span&gt;&lt;br\n  style=\"text-decoration: underline;\"&gt;\nDysplasia in general is divided into low-grade and high-grade&lt;br&gt;\n- on basis of cytological vs architectural&lt;br style=\"font-weight:\n  bold;\"&gt;\nSpread correlates with degree of differentiation.&lt;br&gt;\n- glandular = better than 'diffuse'&lt;br&gt;\n- 'diffuse' type often associated with substrantial stromal\ncomponent.&lt;br&gt;\n- 'Signet ring' = poorly differentiated; bad; more in women, younger\npatients&lt;br&gt;\nLymphovascular invasion is also prognostic.&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-weight: bold;\"&gt;Staging&lt;/span&gt;&lt;span\n  style=\"font-style: italic;\"&gt;&lt;/span&gt;&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"text-decoration: underline;\"&gt;TNM&lt;/span&gt;&lt;br\n  style=\"text-decoration: underline;\"&gt;\n&lt;span style=\"font-style: italic;\"&gt;Tumour&lt;/span&gt;&lt;br&gt;\nTx = unassessable.&lt;br&gt;\nT0 = no primary tumour evident.&lt;br&gt;\nTis = in-situ (intra-epithelial; not invading lamina propria).&lt;br&gt;\nT1 = Invades lamina propria or submucosa.&lt;br&gt;\nT2 = Invades muscularis (T2a) or subserosa (T2b)&lt;br&gt;\nT3 = Invades serosa / visceral peritoneum, but not adjacent\nstructures&lt;br&gt;\nT4 = Invades adjacent structures.&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;Nodes&lt;br&gt;\n&lt;/span&gt;Nx = unassessable&lt;br&gt;\nN0 = no regional nodes&lt;br&gt;\nN1 = 1-6 regional nodes&lt;br&gt;\nN2 = 7-15 nodes&lt;br&gt;\nN3 = &gt;15 nodes&lt;br&gt;\n[need 15 nodes in specimen for accurate staging]&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;Mets&lt;/span&gt;&lt;br&gt;\nMx = unassessable&lt;br&gt;\nM0 = no mets&lt;br&gt;\nM1 = distant mets&lt;span style=\"font-style: italic;\"&gt;&lt;span\n    style=\"font-style: italic;\"&gt;&lt;span style=\"font-style: italic;\"&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;\n&lt;/span&gt; &lt;br&gt;\n&lt;span style=\"text-decoration: underline;\"&gt;Staging&lt;/span&gt;&lt;br&gt;\n0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tis&lt;br&gt;\nIA&nbsp;&nbsp;&nbsp; T1N0M0&lt;br&gt;\nIB&nbsp;&nbsp;&nbsp; T1N1M0, or T2a/bN0M0&lt;br&gt;\nII&nbsp;&nbsp;&nbsp;&nbsp; T1N2M0, T2N1M0, T3N0M0&lt;br&gt;\nIIIA T2N2M0, T3N1M0, T4N0M0&lt;br&gt;\nIIIB&nbsp; T3N2M0&lt;br&gt;\nIV &nbsp;&nbsp; T4N1-3M0, T1-3N3M0, anyTanyNM1&lt;br&gt;\n- ie T4 or N3 or M1 is very bad news.&nbsp; &lt;br&gt;\n&lt;br&gt;\n&lt;center&gt;&lt;a href=\"#top\"&gt;top&lt;/a&gt; &lt;a href=\"#definition\"&gt;D&lt;/a&gt; &lt;a\n    href=\"#incidence\"&gt;I&lt;/a&gt; &lt;a href=\"#aetiology\"&gt;A&lt;/a&gt; &lt;a\n    href=\"#biologicalbehaviour\"&gt;B&lt;/a&gt; &lt;a href=\"#manifestations\"&gt;M&lt;/a&gt;\n  &lt;a href=\"#investigations\"&gt;I&lt;/a&gt; &lt;a href=\"#management\"&gt;M&lt;/a&gt; &lt;a\n    href=\"home.html\"&gt;home&lt;/a&gt;&lt;/center&gt;\n&lt;p&gt; &lt;/p&gt;\n&lt;hr&gt; &lt;b&gt;&lt;a name=\"management\"&gt;MANAGEMENT&lt;/a&gt;&lt;/b&gt;&lt;br&gt;\nMultidisciplinary; gastroenterologists, surgeons, oncologists,\nradiologists.&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-weight: bold;\"&gt;Screening? &lt;/span&gt;&lt;br&gt;\nDone in Japan&nbsp; with mobile X-ray unit and double contrast\nstudy, increasing early diagnosis and survival rates.&lt;br&gt;\nHowever, not justified as overall benefit is minimal, and at present\neven in dyspeptic sufferers, not sufficiently feasible.&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-weight: bold;\"&gt;Surgical&lt;br&gt;\n  &lt;br&gt;\n&lt;/span&gt;&lt;span style=\"text-decoration: underline;\"&gt;Principles&lt;/span&gt;&lt;br&gt;\nSurgical excision remains the cornerstone of curative therapy.&lt;br&gt;\n- possible in &lt;25%&lt;br&gt;\nWant an R0 resection, radical lymphadenectomy, 5cm margin (due to\nsubmucosal spread).&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;What do do with R1 resection?&lt;br&gt;\n  &lt;span style=\"font-style: italic;\"&gt;&lt;/span&gt;&lt;/span&gt;Controversial.&nbsp;\n\n\n\nDecide based on patient's overall condition and treatment goals &lt;br&gt;\n- makes little difference when there is advanced disease.&lt;br&gt;\n- but if early tumour / good lymph status and fit for surgery,\nconsider it.&lt;span style=\"font-style: italic;\"&gt;&lt;span\n    style=\"font-style: italic;\"&gt;&lt;/span&gt;&lt;br&gt;\n&lt;/span&gt;&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;Procedure&lt;/span&gt;&lt;span\n  style=\"font-style: italic;\"&gt;&lt;/span&gt;&lt;br&gt;\nSee &lt;a href=\"Gastrectomy.html\"&gt;gastrectomy&lt;/a&gt;&lt;br&gt;\n&lt;br&gt;\n&lt;i&gt;Role of proximal partial gastrectomy?&lt;/i&gt;&lt;br&gt;\nIntractable reflux limits utility.&lt;br&gt;\nAvoided generally.&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;Extent of Lymphadenectomy?&lt;/span&gt;&lt;br\n  style=\"font-style: italic;\"&gt;\nRemains controversial.&lt;br&gt;\nD0 = no nodes, i.e. palliative resection&lt;br&gt;\nD1 = excision of perigastric nodes&lt;br&gt;\nD2 = nodes along trunks of coeliac axis.&lt;br&gt;\nRadical in Japan, where evidence supports D2 clearance.&lt;br&gt;\nMost Western surgeons are skeptical of radical lymph resections.&lt;br&gt;\n- Dutch Gastric Cancer Group failed to show benefit of D2&gt;D1 in\nsurvival or recurrence-free survival, but did show higher morbidity.&lt;br&gt;\n- Similar results from British Medical Research Council Trial.&lt;br&gt;\n--&gt; distal pancreatectomy and splenectomy were included;\ncontributed to morbidity.&lt;br&gt;\n--&gt; when not included, non-randomized trials show comparable\nmorbidity D1=D2 and improved survival.&lt;br&gt;\nAggressive lymphadenectomy allows adequate staging.&lt;br&gt;\n- No. +ve nodes, regardless of location determines survival.&lt;br&gt;\nNeed at least 15 nodes for accurate staging and improved survival at\nall disease stages.&lt;br&gt;\n--&gt; likely due to less understaging&lt;br&gt;\nHowever, new long-term follow-up data emerging that may state\nvery-long-term survival benefit weighs in favour of D2, unclear.&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;Frozen Section?&lt;/span&gt;&lt;br&gt;\nGood practice to send routine frozen section to ensure R0 resection.&lt;br&gt;\n- before constructing anastomosis; may need extension.&lt;br&gt;\n&lt;br&gt;\n&lt;i&gt;EMR?&lt;/i&gt;&lt;br&gt;\nEmerging role, currently mainly in Japan where tumours diagnosed\nvery early.&lt;br&gt;\nLittle role in West where most are found late&lt;br&gt;\nAlso require highly specialist center and some may not be amenable,\nsuch as GOJ tumours or at high curvatures.&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"text-decoration: underline;\"&gt;Palliative Surgery?&lt;/span&gt;&lt;br\n  style=\"text-decoration: underline;\"&gt;\nControversial.&lt;br&gt;\nNo role at present; no evidence of survival and cannot be justified\nfor QOL.&lt;br&gt;\nSignificant morbidity (50% complications)&lt;br&gt;\nObservational studies show only 10% of those who have operations\naborted will undergo subsequent surgical intervention.&lt;br&gt;\nIf obstructs, stent is best option.&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-weight: bold;\"&gt;Adjuvant Therapy&lt;/span&gt;&lt;span\n  style=\"font-weight: bold; text-decoration: underline;\"&gt;&lt;br\n    style=\"font-weight: bold; text-decoration: underline;\"&gt;\n&lt;/span&gt;Many R0 patients have recurrent disease in &lt;2 yrs, hence\nadjuvant focus.&lt;br&gt;\nSurvival benefit was initially not shown on RCTs for chemo/rad.&lt;br&gt;\nIntergroup 116 trial showed both overall and relapse-free survival\nbetter with 5-FU and lecovorin with external beam radRx.&lt;br&gt;\n--&gt; now standard of care in US&lt;br&gt;\n--&gt; however, muddied by poor quality and standardization of\nmedical therapy; 54% had R0, only 10% R2.&lt;br&gt;\nNewer trials from Japan beginning to show promise using different\nagents.&lt;br&gt;\n- however, relevance to non-D2 population in West unclear.&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;Bottom line:&lt;/span&gt;&lt;br&gt;\nWhen accurately staged and standardized lymph resection, adjuvant\nchemorad not known to clearly surpass that of surgery alone.&lt;br&gt;\nThis is the focus of the Top Gear study, contributing out of\nAustralia&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-weight: bold;\"&gt;Neoadjuvant Therapy&lt;/span&gt;&lt;br&gt;\n&gt;1/3 patients cannot tolerate post-op chemo; better tolerated\npre-op.&lt;br&gt;\nBetter tolerance, can assess disease response in-vivo, downstaging\npotential.&lt;br&gt;\nMAGIC trial (British Medical Council Adjuvant Gastric Infusional\nChemo) = periop epirubicin, cisplatin, 5-FU, vs surgery alone =\nbetter overall and progression free survival, and better\nresectability.&lt;br&gt;\n&lt;span style=\"font-style: italic;\"&gt;Bottom line&lt;/span&gt;:&lt;br&gt;\n--&gt; Give neoadjuvant chemo for patients with T2 or higher\ntumours.&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-weight: bold;\"&gt;Prognosis&lt;/span&gt;&lt;br&gt;\nNomogram on p84 of Cameron.&lt;br&gt;\n- Age (the young and very old do worse)&lt;br&gt;\n- Sex (Men worse)&lt;br&gt;\n- Primary site (GEJ bad)&lt;br&gt;\n- Lauren (Diffuse worse)&lt;br&gt;\n- Size (20 = bad)&lt;br&gt;\n- Nodes (5 = bad, &gt;10 = very bad)&lt;br&gt;\n- Depth (deeper = very bad)&lt;br&gt;\n&lt;br&gt;\n&lt;span style=\"font-weight: bold;\"&gt;Palliation&lt;/span&gt;&lt;br&gt;\nMany elderly with lymph spread, contra-indicating surgery.&lt;br&gt;\nPalliation, pain relief, relief of dysphagia, referral to med onc.&lt;br&gt;\nIn advanced metastatic disease, mild chemo may help; 5-fluorouacil\nand cisplatin.&lt;br&gt;\nGenerally gastric CA radioresistive, though it has some role in\npalliation.&lt;br&gt;\n&lt;br&gt;\n&lt;center&gt;&lt;a href=\"#top\"&gt;top&lt;/a&gt; &lt;a href=\"#definition\"&gt;D&lt;/a&gt; &lt;a\n    href=\"#incidence\"&gt;I&lt;/a&gt; &lt;a href=\"#aetiology\"&gt;A&lt;/a&gt; &lt;a\n    href=\"#biologicalbehaviour\"&gt;B&lt;/a&gt; &lt;a href=\"#manifestations\"&gt;M&lt;/a&gt;\n  &lt;a href=\"#investigations\"&gt;I&lt;/a&gt; &lt;a href=\"#management\"&gt;M&lt;/a&gt; &lt;a\n    href=\"home.html\"&gt;home&lt;/a&gt;&lt;/center&gt;\n&lt;p&gt; &lt;/p&gt;\n&lt;hr&gt;&lt;span style=\"font-weight: bold;\"&gt;References&lt;/span&gt;&lt;br&gt;\nCameron&lt;br&gt;\n&lt;hr style=\"width: 100%; height: 2px;\"&gt;&lt;br&gt;",
    "crumbs": [
      "<span class='chapter-number'>2</span>  <span class='chapter-title'>Gastric Cancer</span>"
    ]
  }
]